ArticleMikrochimica acta2025
PDA-integrated Au@Ag with colorimetric/SERS dual-signal enhancement capability for flexible lateral flow immunoassay detection of respiratory viruses.
Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
A core-shell composite nanomaterial PAu@Ag with structural stability was developed by integrating a layer of Au@Ag bimetallic nanoparticles (NPs) on the polydopamine (PDA) surface. The synergy between PDA and Au@Ag with localized surface plasmon resonance (LSPR) improved the colorimetric performance; simultaneously, the nanogap-arranged Au@Ag NPs created a high density of "hotspots", resulting in markedly enhanced SERS activity. The multiplex lateral flow immunoassay (LFIA), based on PAu@Ag colorimetric/SERS dual-enhanced tags, featuring dual-mode detection of rapid qualitative screening (colorimetric) and ultrasensitive quantitative analysis (SERS), demonstrated excellent performance in simultaneously detecting two highly transmissible respiratory viruses. The colorimetric and SERS enhanced results were 2 to more than 750 times more sensitive than the non-integrated method (Au@Ag - LFIA) and commercial kits (Au - LFIA and ELISA), along with 100% accuracy in 36 clinical samples detection, making PAu@Ag - LFIA show great potential as a universal and flexible immunodiagnostic of viruses.
Indexed as
Identifiers
41175153What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.